8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 19, 2026·SEC
Armata Pharmaceuticals, Inc.(ARMP)Earnings, Financials & Key Ratios
ARMP•AMEX
$9.15
$331M mkt cap·Price updated May 7, 2026
AboutArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.Show more
- Revenue$5M+14.2%
- EBITDA-$41M-3.0%
- Net Income-$19M+72.6%
- EPS (Diluted)-0.52+72.6%
- Gross Margin-565.37%-819.9%
- EBITDA Margin-794.57%+9.9%
- Operating Margin-820.18%+9.2%
- Net Margin-365.6%+76.0%
- ROIC-44.21%-4.4%
- Interest Coverage-3.95+74.6%
ARMP Key Insights
Armata Pharmaceuticals, Inc. (ARMP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARMP Price & Volume
Armata Pharmaceuticals, Inc. (ARMP) stock price & volume — 10-year historical chart
Loading chart...
ARMP Growth Metrics
Armata Pharmaceuticals, Inc. (ARMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years28.89%
5 Years-
3 Years4.96%
TTM-7.55%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.15%
Return on Capital
10 Years-84.25%
5 Years-59.96%
3 Years-56.74%
Last Year-70.67%
ARMP Recent Earnings
Armata Pharmaceuticals, Inc. (ARMP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
Mar 25, 2026EPS
$0.51
Est $0.19
-168.4%
Revenue
$1M
Est $740,000
+48.6%
Q4 2025
Nov 12, 2025EPS
$0.42
Est $0.42
+0.0%
Revenue
$1M
Est $740,000
+56.6%
Q3 2025
Aug 12, 2025EPS
$0.32
Est $0.39
+17.9%
Revenue
$2M
Est $1M
+57.2%
Q2 2025
May 14, 2025EPS
$0.20
Est $0.38
+47.4%
Revenue
$491,000
Est $1M
-64.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 25, 2026 | $0.51vs $0.19-168.4% | $1Mvs $740,000+48.6% |
| Q4 2025 | Nov 12, 2025 | $0.42vs $0.42+0.0% | $1Mvs $740,000+56.6% |
| Q3 2025 | Aug 12, 2025 | $0.32vs $0.39+17.9% | $2Mvs $1M+57.2% |
| Q2 2025 | May 14, 2025 | $0.20vs $0.38+47.4% | $491,000vs $1M-64.4% |
Based on last 12 quarters of dataView full earnings history →
ARMP Peer Comparison
Armata Pharmaceuticals, Inc. (ARMP) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PHGE | 1.01B | 0.62 | -0.03 | -274.01% | ||||
 LSTA | 29.41M | 3.23 | -1.69 | -83% | -97.56% | -85.5% | ||
 SIGA | 338.88M | 4.73 | 14.33 | -31.8% | -43117.39% | -10.67% | 0.00 | |
 ACXP | 4.98M | 2.12 | -0.40 | -6.04% | ||||
 INNV | 1.1B | 8.08 | -36.73 | 11.76% | -2.35% | -8.18% | 0.38 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 ADMA | 2.03B | 8.47 | 14.12 | 19.63% | 32.43% | 38.97% | 0.17 |
Compare ARMP vs Peers
Armata Pharmaceuticals, Inc. (ARMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARMP Income Statement
Armata Pharmaceuticals, Inc. (ARMP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 260K | 115K | 0 | 0 | 823K | 4.47M | 5.51M | 4.53M | 5.17M | 5.05M |
| Revenue Growth % | -45.26% | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% | -7.55% |
| Cost of Goods Sold | 369K | 374K | 1.35M | 1.35M | 14.44M | 20.02M | 35.02M | 972K | 34.43M | 1.49M |
| COGS % of Revenue | 141.92% | 325.22% | - | - | 1755.04% | 447.36% | 635.75% | 21.46% | 665.37% | - |
| Gross Profit | -109K▲ 0% | -259K▼ 137.6% | -1.35M▼ 421.6% | -1.35M▲ 0.0% | -13.62M▼ 908.2% | -15.54M▼ 14.1% | -29.51M▼ 89.9% | 3.56M▲ 112.1% | -29.25M▼ 922.4% | 3.56M▲ 0% |
| Gross Margin % | -41.92% | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% | 70.46% |
| Gross Profit Growth % | -122.95% | -137.61% | -421.62% | 0% | -908.22% | -14.1% | -89.88% | 112.05% | -922.38% | - |
| Operating Expenses | 23.64M | 16.27M | 9.54M | 17.74M | 7.97M | 8.28M | 7.44M | 44.45M | 13.18M | 36.91M |
| OpEx % of Revenue | 9091.54% | 14148.7% | - | - | 967.92% | 185.09% | 135.02% | 981.39% | 254.81% | - |
| Selling, General & Admin | 8.41M | 7.59M | 5.7M | 7.91M | 7.97M | 8.28M | 7.44M | 10.68M | 13.18M | 11.94M |
| SG&A % of Revenue | 3235.77% | 6600% | - | - | 967.92% | 185.09% | 135.02% | 235.75% | 254.81% | - |
| Research & Development | 5.68M | 2.88M | 4.89M | 9.82M | 14.44M | 20.02M | 35.02M | 33.77M | 34.43M | 26.1M |
| R&D % of Revenue | 2183.85% | 2505.22% | - | - | 1755.04% | 447.36% | 635.75% | 745.64% | 665.37% | - |
| Other Operating Expenses | -554K | 6K | -1.4M | 0 | -14.44M | -20.02M | -35.02M | 0 | -34.43M | -1.12M |
| Operating Income | -23.38M▲ 0% | -16.16M▲ 30.9% | -12.52M▲ 22.5% | -19.09M▼ 52.4% | -21.59M▼ 13.1% | -23.82M▼ 10.4% | -36.95M▼ 55.1% | -40.89M▼ 10.7% | -42.44M▼ 3.8% | -33.35M▲ 0% |
| Operating Margin % | -8991.54% | -14048.7% | - | - | -2622.96% | -532.45% | -670.77% | -902.85% | -820.18% | -659.87% |
| Operating Income Growth % | -128.59% | 30.89% | 22.48% | -52.42% | -13.09% | -10.35% | -55.09% | -10.67% | -3.78% | - |
| EBITDA | -23.01M | -15.78M | -11.17M | -17.74M | -20.47M | -22.65M | -36.05M | -39.92M | -41.11M | -31.86M |
| EBITDA Margin % | -8849.62% | -13723.48% | - | - | -2487.61% | -506.33% | -654.58% | -881.39% | -794.57% | -630.33% |
| EBITDA Growth % | -132.48% | 31.41% | 29.2% | -58.76% | -15.42% | -10.65% | -59.16% | -10.72% | -2.99% | 20.83% |
| D&A (Non-Cash Add-back) | 369K | 374K | 1.35M | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M | 1.49M |
| EBIT | -13.83M | -10.36M | -10.89M | -18.55M | -21.55M | -23.09M | -36.95M | -66.42M | -42.44M | -31.86M |
| Net Interest Income | 0 | 0 | 0 | -835K | -600K | -59K | 0 | -2.45M | -10.04M | -14.65M |
| Interest Income | 0 | 0 | 0 | 96K | 28K | 5K | 29K | 179K | 697K | 387K |
| Interest Expense | 0 | 0 | 0 | 931K | 628K | 64K | 29K | 2.63M | 10.74M | 15.04M |
| Other Income/Expense | 3.98M | 2.02M | 956K | -390K | -594K | 667K | 29K | -28.16M | 23.52M | -13.55M |
| Pretax Income | -19.39M▲ 0% | -14.14M▲ 27.1% | -16.7M▼ 18.1% | -19.48M▼ 16.6% | -22.18M▼ 13.9% | -23.16M▼ 4.4% | -36.92M▼ 59.4% | -69.05M▼ 87.0% | -18.92M▲ 72.6% | -46.9M▲ 0% |
| Pretax Margin % | -7459.23% | -12295.65% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -928% |
| Income Tax | -556K | -1.3M | -328K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 2.87% | 9.21% | 1.96% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.84M▲ 0% | -12.84M▲ 31.9% | -12.11M▲ 5.7% | -19.48M▼ 60.9% | -22.18M▼ 13.9% | -23.16M▼ 4.4% | -36.92M▼ 59.4% | -69.05M▼ 87.0% | -18.92M▲ 72.6% | -46.9M▲ 0% |
| Net Margin % | -7245.38% | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -928% |
| Net Income Growth % | -3550.78% | 31.85% | 5.67% | -60.85% | -13.87% | -4.39% | -59.43% | -87.03% | 72.6% | -13.39% |
| Net Income (Continuing) | -18.84M | -12.84M | -16.7M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M | -46.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -345.80▲ 0% | -27.34▲ 92.1% | -8.90▲ 67.4% | -2.43▲ 72.7% | -1.35▲ 44.4% | -0.96▲ 28.9% | -1.08▼ 12.5% | -1.91▼ 76.9% | -0.52▲ 72.6% | -1.29▲ 0% |
| EPS Growth % | -24.12% | 92.09% | 67.45% | 72.7% | 44.44% | 28.89% | -12.5% | -76.85% | 72.61% | 19.15% |
| EPS (Basic) | -345.80 | -28.14 | -8.90 | -2.43 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 | - |
| Diluted Shares Outstanding | 70.28K | 456.24K | 1.36M | 8.01M | 16.41M | 24.1M | 34.29M | 36.08M | 36.16M | 36.23M |
| Basic Shares Outstanding | 70.28K | 456.25K | 1.36M | 7.83M | 16.41M | 24.1M | 34.29M | 36.08M | 36.16M | 36.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARMP Balance Sheet
Armata Pharmaceuticals, Inc. (ARMP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.36M | 5.38M | 8.41M | 6.66M | 10.85M | 14.99M | 27.05M | 19.15M | 11.31M | 16.93M |
| Cash & Short-Term Investments | 5.71M | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M | 14.76M |
| Cash Only | 5.71M | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M | 14.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 25K | 0 | 0 | 0 | 561K | 2.99M | 1.94M | 3.36M | 744K | 759K |
| Days Sales Outstanding | 35.1 | - | - | - | 248.8 | 243.85 | 128.29 | 271.03 | 52.49 | 70.58 |
| Inventory | -619K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 602K | 253K | 0 | 622K | 0 | 0 | 10.26M | 2.27M | 1.27M | 1.42M |
| Total Non-Current Assets | 11.84M | 5.75M | 3.48M | 18.8M | 28.67M | 54.77M | 80.83M | 79.21M | 75.13M | 72.59M |
| Property, Plant & Equipment | 1.07M | 816K | 503K | 4.21M | 12.84M | 38.07M | 46.65M | 57.28M | 54.93M | 52.48M |
| Fixed Asset Turnover | 0.24x | 0.14x | - | - | 0.06x | 0.12x | 0.12x | 0.08x | 0.09x | 0.09x |
| Goodwill | 0 | 0 | 0 | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M |
| Intangible Assets | 10.77M | 4.94M | 2.98M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M |
| Long-Term Investments | 0 | 0 | 800K | 700K | 1.2M | 0 | 5.96M | 0 | 5.48M | 10.87M |
| Other Non-Current Assets | 0 | 0 | 136K | 135K | -2.13M | 2.96M | 2.43M | 8.19M | 975K | 14.68M |
| Total Assets | 18.2M▲ 0% | 11.14M▼ 38.8% | 11.89M▲ 6.7% | 25.45M▲ 114.1% | 39.52M▲ 55.3% | 69.77M▲ 76.6% | 107.88M▲ 54.6% | 98.36M▼ 8.8% | 86.44M▼ 12.1% | 89.52M▲ 0% |
| Asset Turnover | 0.01x | 0.01x | - | - | 0.02x | 0.06x | 0.05x | 0.05x | 0.06x | 0.06x |
| Asset Growth % | -42.23% | -38.79% | 6.72% | 114.11% | 55.26% | 76.56% | 54.62% | -8.82% | -12.12% | -73.92% |
| Total Current Liabilities | 3.58M | 1.97M | 2.57M | 4.88M | 6.71M | 4.81M | 24.87M | 16.46M | 48.25M | 139.95M |
| Accounts Payable | 1.06M | 578K | 729K | 547K | 956K | 1.14M | 6.03M | 1.58M | 766K | 1.28M |
| Days Payables Outstanding | 1.04K | 564.09 | 196.95 | 147.78 | 24.16 | 20.75 | 62.9 | 595.19 | 8.12 | 243.99 |
| Short-Term Debt | 803K | 0 | 0 | 1.31M | 722K | 0 | 17.01M | 0 | 38.95M | 131.08M |
| Deferred Revenue (Current) | 933K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 826K | 340K | 1.35M | 1.7M | 1.94M | 0 | 0 | 1.29M | 529K | 2.35M |
| Current Ratio | 1.78x | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x | 0.23x |
| Quick Ratio | 1.95x | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x | 0.23x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -173.41 |
| Total Non-Current Liabilities | 4.89M | 1.44M | 841K | 5.98M | 13.95M | 39.56M | 46.92M | 113.97M | 86.21M | 45.15M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 82.31M | 55.44M | 15.24M |
| Capital Lease Obligations | 0 | 0 | 0 | 1.55M | 10.88M | 36.48M | 31.8M | 28.58M | 27.69M | 109.08M |
| Deferred Tax Liabilities | 2.45M | 1.15M | 819K | 3.08M | 3.08M | 3.08M | 15.12M | 3.08M | 3.08M | 12.31M |
| Other Non-Current Liabilities | 2.44M | 292K | 22K | 1.35M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.47M | 3.41M | 3.41M | 10.86M | 20.66M | 44.37M | 71.8M | 130.43M | 134.46M | 185.1M |
| Total Debt | 803K | 0 | 0 | 2.86M | 13.15M | 37.99M | 48.81M | 120.37M | 126.52M | 177.68M |
| Net Debt | -4.91M | -5.13M | -8.16M | -3.17M | 3.5M | 27.7M | 33.96M | 106.85M | 117.22M | 162.93M |
| Debt / Equity | 0.08x | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - | -1.86x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.58x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.11x |
| Interest Coverage | - | - | - | -20.50x | -34.37x | -372.22x | -1274.00x | -15.57x | -3.95x | -2.12x |
| Total Equity | 9.72M▲ 0% | 7.73M▼ 20.5% | 8.47M▲ 9.6% | 14.59M▲ 72.2% | 18.86M▲ 29.2% | 25.4M▲ 34.7% | 36.08M▲ 42.1% | -32.06M▼ 188.9% | -48.02M▼ 49.8% | -95.59M▲ 0% |
| Equity Growth % | -23.53% | -20.49% | 9.61% | 72.21% | 29.22% | 34.68% | 42.06% | -188.87% | -49.76% | -183.22% |
| Book Value per Share | 138.36 | 16.94 | 6.23 | 1.82 | 1.15 | 1.05 | 1.05 | -0.89 | -1.33 | -2.64 |
| Total Shareholders' Equity | 9.72M | 7.73M | 8.47M | 14.59M | 18.86M | 25.4M | 36.08M | -32.06M | -48.02M | -95.59M |
| Common Stock | 165K | 95K | 323K | 99K | 187K | 271K | 361K | 361K | 362K | 362K |
| Retained Earnings | -381.36M | -394.21M | -406.32M | -157.52M | -179.7M | -202.86M | -239.77M | -308.82M | -327.74M | -377.24M |
| Treasury Stock | 0 | -401.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18.2M | -11.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARMP Cash Flow Statement
Armata Pharmaceuticals, Inc. (ARMP) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.59M | -9.19M | -9.38M | -15.58M | -18.27M | -23.57M | -32.48M | -47.42M | -37.55M | -37.55M |
| Operating CF Margin % | -4072.69% | -7993.04% | - | - | -2219.93% | -526.93% | -589.71% | -1047.1% | -725.76% | - |
| Operating CF Growth % | -8.26% | 13.19% | -2.07% | -66.08% | -17.25% | -29.04% | -37.78% | -46% | 20.82% | 111.24% |
| Net Income | -18.84M | -12.84M | -12.11M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M | -46.9M |
| Depreciation & Amortization | 369K | 374K | 389K | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M | 1.49M |
| Stock-Based Compensation | 2M | 700K | 478K | 4.27M | 3.48M | 2.88M | 3.1M | 938K | 2.89M | 2.33M |
| Deferred Taxes | -556K | -1.3M | -328K | -454K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.77M | 4.33M | 1.84M | 918K | 196K | -1.25M | 0 | 29.36M | -20.75M | 16.25M |
| Working Capital Changes | 670K | -457K | 345K | -2.19M | -874K | -3.22M | 439K | -9.65M | -2.1M | -190K |
| Change in Receivables | 100K | 381K | 0 | 0 | -467K | -2.43M | 1.05M | 0 | 0 | 0 |
| Change in Inventory | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 298K | -838K | 343K | -1.37M | 544K | 184K | 3.67M | 39K | -3.75M | -1.75M |
| Cash from Investing | -279K | -58K | -44K | 2.88M | -824K | -1.3M | -2.21M | -8.13M | -1.88M | -413K |
| Capital Expenditures | -279K | -58K | -44K | -131K | -824K | -1.3M | -2.21M | -8.14M | -1.88M | -413K |
| CapEx % of Revenue | 107.31% | 50.43% | - | - | 100.12% | 29.15% | 40.14% | 179.82% | 36.32% | - |
| Acquisitions | 0 | 0 | 65K | 3.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.91M | 9.69M | 0 | 0 | 0 | 0 | 10K | 0 | 0 |
| Cash from Financing | 7.21M | 8.67M | 12.45M | 8.97M | 23.21M | 25.52M | 44.02M | 53.99M | 34.96M | 24.95M |
| Debt Issued (Net) | -100K | -815K | 0 | 0 | 717K | 0 | 0 | 54.03M | 34.89M | -9.89M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 5K | 130K | -14K |
| Dividends Paid | -80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14K |
| Other Financing | 13K | 133K | 203K | -1M | -400K | -801K | -500K | -43K | -61K | 34.86M |
| Net Change in Cash | -3.66M▲ 0% | -579K▲ 84.2% | 3.02M▲ 622.5% | -3.73M▼ 223.3% | 4.12M▲ 210.3% | 639K▼ 84.5% | 4.56M▲ 614.2% | -1.57M▼ 134.4% | -4.47M▼ 185.0% | -2.48M▲ 0% |
| Free Cash Flow | -10.87M▲ 0% | -9.25M▲ 14.9% | -9.43M▼ 1.9% | -15.71M▼ 66.7% | -19.09M▼ 21.5% | -24.88M▼ 30.3% | -34.69M▼ 39.4% | -55.57M▼ 60.2% | -39.43M▲ 29.0% | -27.43M▲ 0% |
| FCF Margin % | -4180% | -8043.48% | - | - | -2320.05% | -556.08% | -629.85% | -1226.92% | -762.08% | -542.72% |
| FCF Growth % | -8.78% | 14.89% | -1.9% | -66.7% | -21.52% | -30.3% | -39.44% | -60.17% | 29.04% | 34.83% |
| FCF per Share | -154.65 | -20.27 | -6.93 | -1.96 | -1.16 | -1.03 | -1.01 | -1.54 | -1.09 | -1.09 |
| FCF Conversion (FCF/Net Income) | 0.56x | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x | 0.58x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARMP Key Ratios
Armata Pharmaceuticals, Inc. (ARMP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -167.92% | -147.11% | -149.46% | -168.89% | -132.62% | -104.65% | -120.1% | -3439.35% | - | 70.29% |
| Return on Invested Capital (ROIC) | -429.8% | -326.87% | -644.24% | -243.9% | -95.85% | -47.36% | -45% | -42.35% | -44.21% | -44.21% |
| Gross Margin | -41.92% | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% | 70.46% |
| Net Margin | -7245.38% | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% | -928% |
| Debt / Equity | 0.08x | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - | -1.86x |
| Interest Coverage | - | - | - | -20.50x | -34.37x | -372.22x | -1274.00x | -15.57x | -3.95x | -2.12x |
| FCF Conversion | 0.56x | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x | 0.58x |
| Revenue Growth | -45.26% | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% | -7.55% |
ARMP SEC Filings & Documents
Armata Pharmaceuticals, Inc. (ARMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARMP Frequently Asked Questions
Armata Pharmaceuticals, Inc. (ARMP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Armata Pharmaceuticals, Inc. (ARMP) reported $5.1M in revenue for fiscal year 2024. This represents a 4954% increase from $0.1M in 1993.
Armata Pharmaceuticals, Inc. (ARMP) grew revenue by 14.2% over the past year. This is steady growth.
Armata Pharmaceuticals, Inc. (ARMP) reported a net loss of $46.9M for fiscal year 2024.
Dividend & Returns
Armata Pharmaceuticals, Inc. (ARMP) had negative free cash flow of $27.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More ARMP
Armata Pharmaceuticals, Inc. (ARMP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates